TNF and ocular melanoma: Thus, in this study, we treated VSMCs with TNFα in OM for 1 day to promote VSMCs loss of contractile phenotypic markers and then utilized SB505124 (a selective inhibitor of TGFβ type I receptors) with OM to induce VSMCs to transdifferentiate into an osteogenic phenotype (Figure 3A).